Taro Pharmaceutical Industries (NYSE: TARO) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Taro Pharmaceutical Industries to similar businesses based on the strength of its dividends, institutional ownership, risk, profitability, valuation, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Taro Pharmaceutical Industries and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Taro Pharmaceutical Industries 0 1 0 0 2.00
Taro Pharmaceutical Industries Competitors 846 3755 6778 185 2.54

As a group, “Pharmaceuticals” companies have a potential upside of 21.39%. Given Taro Pharmaceutical Industries’ peers stronger consensus rating and higher probable upside, analysts clearly believe Taro Pharmaceutical Industries has less favorable growth aspects than its peers.

Valuation and Earnings

This table compares Taro Pharmaceutical Industries and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Taro Pharmaceutical Industries $879.39 million $456.35 million 11.66
Taro Pharmaceutical Industries Competitors $8.39 billion $1.12 billion 133.21

Taro Pharmaceutical Industries’ peers have higher revenue and earnings than Taro Pharmaceutical Industries. Taro Pharmaceutical Industries is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

14.2% of Taro Pharmaceutical Industries shares are held by institutional investors. Comparatively, 42.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are held by company insiders. Comparatively, 11.7% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Taro Pharmaceutical Industries and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Taro Pharmaceutical Industries 49.69% 19.71% 17.74%
Taro Pharmaceutical Industries Competitors -2,925.59% -70.76% -9.78%

Volatility & Risk

Taro Pharmaceutical Industries has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries’ peers have a beta of 32.56, meaning that their average share price is 3,156% more volatile than the S&P 500.

Summary

Taro Pharmaceutical Industries peers beat Taro Pharmaceutical Industries on 9 of the 13 factors compared.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company’s owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company’s other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.